By a News Reporter-Staff News Editor at Biotech Week -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced it has appointed Gregg Alton and Graham Cooper to its Board of Directors (see also Celladon Corporation).
"We are pleased to appoint Gregg and Graham to our Board of Directors," commented Krisztina Zsebo Ph.D., President and CEO of Celladon. "They each bring extensive experience in the biotechnology industry and we expect they will provide valuable strategic contributions to our Board."
Gregg Alton is currently executive vice president of corporate and medical affairs and chief compliance officer at Gilead Sciences, a position he has held since August 2009. From 2000 to 2009, Mr. Alton held various positions with Gilead, including associate general counsel, general counsel, vice president and senior vice president. Earlier in his career, Mr. Alton was an associate at the law firms of Cooley LLP and Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. where he advised and represented biotechnology clients in a wide range of corporate transactions. Mr. Alton currently serves on the boards of directors of Gilead Healthcare PAC, the Gilead Foundation, the AIDS Institute and BayBio, a San Francisco life sciences industry organization. He also serves as a member of the Advisory Board of the University of California, San Francisco Global Health Group and the Dean's Advisory Council at Stanford Law School. Mr. Alton received a B.A. from the University of California, Berkeley and a J.D. from Stanford Law School.
Graham Cooper is currently chief financial officer at Receptos Corporation, a biopharmaceutical company focused on therapeutics for immune disorders. Mr. Cooper served as executive vice president of finance and chief financial officer at Geron Corporation during 2012, a biopharmaceutical company focused on cancer therapies. From 2006 to 2011, Mr. Cooper served as senior vice president, chief financial officer and treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity therapeutics. Previously, Mr. Cooper held positions of increasing responsibility, including director, health care investment banking, at Deutsche Bank Securities, a leading global investment bank, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. Previously, he worked in audit and accounting services at Deloitte & Touche LLP, an independent registered public accounting firm, and was previously a C.P.A. Mr. Cooper holds a B.A. in economics from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business.
Keywords for this news article include: Biotechnology, Drugs, Therapy, Biopharmaceuticals, Celladon Corporation, Investment and Finance.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC